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Abstract
Background -We evaluated the viability of IKur as a target for maintenance of sinus rhythm in 
patients with a history of atrial fibrillation through the testing of MK-0448, a novel IKur inhibitor.   
Methods and Results - In vitro MK-0448 studies demonstrated strong inhibition of IKur with 
minimal off-target activity.  In vivo MK-0448 studies in normal anesthetized dogs demonstrated 
significant prolongation of the atrial refractory period compared with vehicle controls without 
affecting the ventricular refractory period.  In studies of a conscious dog heart failure model, 
sustained AF was terminated with bolus intravenous MK-0448 doses of 0.03 and 0.1 mg/kg. 
These data led to a two-part "first-in-human" study: Part I evaluated safety and 
pharmacokinetics, and Part II was an invasive electrophysiologic (EP) study in healthy subjects.  
MK-0448 was well-tolerated with mild adverse experiences, most commonly irritation at the 
injection site.  During the EP study, ascending doses of MK-0448 were administered, but no 
increases in atrial or ventricular refractoriness were detected despite achieving plasma 
?????????????????????????????????????????-up studies in normal anesthetized dogs designed to 
assess the influence of autonomic tone demonstrated that prolongation of atrial refractoriness 
with MK-0448 was markedly attenuated in the presence of vagal nerve simulation, suggesting 
that the effects of IKur blockade on atrial repolarization may be negated by enhanced 
parasympathetic neural tone.  
Conclusions - The contribution of IKur to human atrial electrophysiology is less prominent than 
in preclinical models and therefore is likely to be of limited therapeutic value for the prevention 
of atrial fibrillation.  
Key words: arrhythmia; atrial fibrillation; electrophysiology; pharmacokinetics
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Atrial fibrillation, the most common sustained cardiac arrhythmia, is associated with 
considerable morbidity as well as mortality.1-3  This condition may be effectively managed by 
either rhythm control (cardioversion) or rate control, depending on the patient profile.  For 
patients who are appropriate candidates for cardioversion, there are several strategies for 
conversion of atrial fibrillation to sinus rhythm, including electrical or pharmacologic methods.4
Currently available pharmacotherapies include flecainide, propafenone, amiodarone, and 
ibutilide, which are sodium channel blockers that block sodium ion channel proteins such as 
Nav1.5 and/or potassium channel blockers that block the rapidly activating delayed rectifier 
cardiac potassium current (IKr) and/or the slowly activating delayed rectifier cardiac potassium 
current (IKs).5,6 While these agents have modest efficacy in restoring sinus rhythm, they also 
have unwanted effects on ventricular depolarization (QRS widening due to slowed conduction) 
and repolarization (QT interval prolongation), which may lead to ventricular arrhythmias such as 
ventricular tachycardia or torsade de pointes, particularly in patients with structural heart 
disease.4,7,8
Due to the risk of these serious adverse effects, a more targeted approach to therapy is an 
important goal.8 IKur is an ultra-rapid delayed rectifier current that is different from other currents 
such as IKr due to its presence in atrial myocytes but absence in ventricular tissue.9 Blockade of 
IKur has been shown to selectively prolong atrial refractoriness without affecting ventricular 
repolarization and appears to be an effective antiarrhythmic strategy for the acute conversion of 
atrial fibrillation in animal models.10 For these reasons, IKur blockade may represent an atrial-
specific strategy that can lead to therapies that are effective in converting atrial fibrillation yet do
not have ventricular effects.  However, research into this target has led to contradictory evidence, 
suggesting that suppression of IKur in certain circumstances may promote rather than prevent 
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atrial fibrillation.  A loss-of-function mutation in KCNA5, the gene that encodes Kv1.5 channels 
responsible for IKur, has been described in a familial case of atrial fibrillation.11 In isolated 
human atrial myocytes, exposure to 4-aminopyridine at concentrations reported to selectively 
block IKur resulted in action potential prolongation, a propensity to elicit early after-
depolarizations and triggered activity with co-exposure to isoproterenol.11 Similarly in normal 
mice, the intraperitoneal administration of 4-aminopyridine provoked premature atrial 
complexes, with atrial fibrillation induced by co-administration of isoproterenol.11  Further, 
experimental evidence has shown that exposure to 4-aminopyridine allowed induction of atrial 
fibrillation in healthy isolated canine coronary-perfused right atrial preparations and failed to 
terminate fibrillation in remodeled atrial preparations.12 Data from Wettwer et al suggest that 
whether inhibition of IKur prolongs or shortens action potential duration (APD) depends on the 
disease status of the atria and is determined by the level of electrical remodeling.13 They 
concluded that IKur blockade shortens action potential duration at 90% (APD90) in sinus rhythm, 
but prolongs it in AF.  This is probably due to the observation that normal (healthy) atria 
typically displayed action potentials with a prominent plateau, whereas remodeled atria displayed 
triangular-shaped APs.12
We developed MK-0448 (N-{6-[(1S)-1-(4-fluorophenyl)-2,2-di(pyridin-3-
yl)ethyl]pyridin-2-yl}methanesulfonamide) in order to test the hypothesis that specific blockade 
of IKur would be an effective pharmacologic approach for the termination and/or prevention of 
atrial fibrillation without the ventricular effects that are associated with other anti-arrhythmics.  
MK-0448 is an agent that is structurally related to triarylethanolamine, 2-phenyl-1,1-dipyridin-3-
yl-2-pyrrolidin-1-yl-ethanol (TAEA), a probe compound demonstrated to have atrial specificity 
and anti-arrhythmic activity in an animal model of atrial fibrillation.10 TAEA was the basis for 
DOI: 10.1161/CIRCEP.111.969782
5
MK-0448, which was generated to optimize various pharmacokinetic properties while 
maintaining specificity for Kv1.5, a potassium channel that is responsible for IKur.14
Additionally, isoquinolinone (ISQ-1), a structurally distinct compound that also targets Kv1.5, 
was also previously shown to be significantly more effective at terminating atrial fibrillation than 
placebo in a dog heart failure AF model.10 We conducted in vitro and in vivo studies, as well as 
first-in-human studies with electrophysiologic testing using MK-0448 to examine whether 
blockade of Kv1.5 (and hence IKur) would increase atrial refractoriness and thereby demonstrate 
potential as a treatment for atrial fibrillation in humans. 
Methods
Preclinical Program
Detailed methodologies for preclinical in vitro studies are provided in Appendix 1.  Presented 
here is a summary of methods for the in vitro and in vivo studies.   
In vitro Studies 
Inhibition of currents carried by heterologously expressed Kv1.5 and native IKur channels was 
assessed using Chinese hamster ovary (CHO) cells and human atrial myocytes, respectively, in 
functional voltage-clamp assays with traditional patch-clamp electrophysiological methods to 
determine potency.  Ventricular repolarization was studied through testing effects on hERG 
channels heterologously expressed in CHO-K1 cells using standard whole-cell voltage clamp 
techniques.  Current amplitudes recorded pre-drug and post-drug were compared pair-wise to 
determine inhibitory effect. Percent inhibition of the peak control current was plotted as a 
function of compound concentration and the concentration of drug required to inhibit current by 
50 % (IC50) was determined by fitting of the Hill equation to the concentration response data:  %
of Control = 100 ? (1 + ([Drug]/IC50) p )-1.  We also tested effects on slowly activating cardiac 
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delayed rectifier K+ current, IKs, resulting from the stable co-expression of the ion channel 
subunits hKCNQ1 and hKCNE1 in HEK-293 host cell line.  Specific assays for IK1, Ito, INa,
Kv3.2, IKCa, Kv2.1, Kv1.7, and NR1a/2B were also performed. 
In vivo Studies
Cardiac Electrophysiological Studies in Anesthetized Dogs
The electrocardiographic and cardiac electrophysiological effects of MK-0448 were compared 
with vehicle-matched control infusions in anesthetized male or female mongrel dogs (6.3-12.1 
kg). The surgical preparation and methods for the measurement of cardiac electrophysiologic 
parameters in anesthetized dogs were as described previously.15 Dogs were anesthetized with ?-
chloralose (100 mg/kg i.v.) and minimal sodium pentobarbital (5 mg/kg i.v.) to provide 
additional analgesia and anesthesia. A continuous infusion of ?-chloralose (10 mg/kg/hr i.v.) was 
utilized to maintain anesthesia over the time course of the study.15 At 30 min following surgical 
preparation, the following parameters were measured prior to (baseline) and at 15, 30, 45 and 60 
min following initiation of 60 min continuous IV infusions of vehicle or test agent: sinus heart 
rate, mean arterial pressure, ECG intervals including rate-corrected QT interval [(QT in 
?????????-R in sec)], atrial and ventricular excitation thresholds (AET, VET), and atrial and 
ventricular relative refractory periods (ARRP, VRRP).  ARRP and VRRP are commonly used 
measures of refractory period in intact animal cardiac electrophysiology studies (10, 15); in this 
study, they were determined using programmed pacing at a basic S1-S1 cycle length of 400 msec 
(150 bpm), introducing S2 at 2xET and decrementing the S1-S2 initially at 10msec intervals 
followed by 2msec intervals until an S2 extrastimulus could not be propagated.. Blood samples 
for determination of plasma concentrations of MK-0448 by liquid chromatography - tandem 
mass spectrometry (LC/MS/MS) were also obtained at these time points.
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Two temporally distinct sets of in vivo cardiac electrophysiological studies were 
conducted.  Lower dose range studies were conducted in order to determine the 
pharmacologically effective dose/plasma concentration of MK-0448, and consisted of four 
groups of dogs assigned to i.v. treatment with vehicle (25% hydroxypropyl-ß-cyclodextrin 
aqueous; n=6) or MK-0448 at 0.15 (n=4), 0.30 (n=5) or 0.45 μg/kg/min  (n=5) infused at a rate 
of 20 ml/hr.  Subsequently, higher dose range studies were conducted, consisting of three groups 
of dogs assigned to i.v. treatment with vehicle (25% hydroxypropyl-ß-cyclodextrin aqueous; 
n=2) or MK-0448 at 20.0 (n=4) or 30.0 μg/kg/min (n=4) infused at a rate of 20 ml/hr.   
Electrophysiologic Study of Atrial Fibrillation in a Dog Heart Failure Model
The surgical preparation and methods for the production of heart failure by rapid right 
ventricular pacing as well as cardiac electrophysiologic testing and induction of atrial fibrillation 
(AF) by atrial burst pacing are previously described.10 In these 3 animals, MK-0448 dosing was 
initiated after 15 minutes of sustained AF. MK-0448 was administered as 30 sec intravenous 
infusions at 5 min intervals at sequential doses of 0.03, 0.1, 0.3 and 1.0 mg/kg. Blood samples 
were drawn prior to dosing, at termination of AF or at 5 minutes after the highest dose tested if 
AF was not terminated.
First in Human (FIH) Study 
The first in human study (Sponsor Protocol 001) was conducted from August 2005 to February 
2006 following approval by the Thomas Jefferson University (TJU) Investigational Review 
Board and the TJU Hospital and Clinical Pharmacology Unit (CPU) and was conducted in 
accordance with Good Clinical Practice principles.  Prior to enrollment, all patients provided 
written informed consent.   
This was a two-part study.  Part I was done to evaluate the safety and tolerability of 
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intravenous (IV) doses of MK-0448, obtain pharmacokinetic parameters, and to evaluate urinary 
excretion and pharmacodynamic effects on heart rate, blood pressure, and ECG parameters.  Part 
II used novel techniques to evaluate the electrophysiological effects of MK-0448 on atrial and 
ventricular refractory period duration, as well as sinus node, AV node, and His-Purkinje 
function.   
Part I was a double-blind, randomized, placebo-controlled, multiple-period, alternating 
panel, rising-dose study in healthy male subjects.  Two panels (Panels A and B) consisting of 8 
subjects each alternatively received single IV rising infusions of MK-0448 or matching placebo 
in a 3:1 ratio, respectively, in up to 5 treatment periods.  Doses for Panel A were 0.5 mg, 2 mg, 8 
mg, 18 mg, and 32 mg for each successive period.  Doses for Panel B were 1 mg, 4 mg, 12 mg, 
24 mg, and 40 mg for each successive period.  At least 3 days elapsed before administration of 
the next higher dose.  All doses were administered for 2 hours (sterile solution for IV 0.1 mg/ml 
in a 50 mL vial ).   
An additional serial panel (Panel C) was conducted following a satisfactory evaluation of 
safety, tolerability, and preliminary pharmacokinetic data from all doses administered in Panels 
A and B.  Panel C (8 subjects; 6 active, 2 placebo), was administered as single IV infusions for 2 
hours in a 5-period single ascending-dose design with doses at 40 mg, 50 mg, 62 mg, 80 mg, and 
100 mg for each successive period.   
Safety measures included telemetry monitoring, 12-lead ECGs, physical examinations, 
and vital signs including measurement of orthostatic heart rate and blood pressure. During and 
after infusions of MK-0448, specimens were obtained for pharmacokinetic analysis. 
Part II was a placebo-controlled, rising, single-dose study in healthy males (Panel D). 
Doses in Part II (panel D) were about half of the starting doses in Panels A and B in Part 1.  
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Electrophysiology studies were performed after overnight fasting. Caffeinated beverages and 
tobacco use were not allowed during the study period.  The starting dose for Part II was selected 
to target a Ceoi (concentration at the end of infusion) of 100 nM based on the pharmacokinetic 
data from Part I and was expected to be ~2 mg delivered over 2 hours, based on allometric 
scaling of pharmacokinetic data from preclinical experiments.  Each subject had 3 venous 
sheaths placed percutaneously in the femoral veins after infiltration of lidocaine without 
epinephrine.  None of the subjects received systemic anesthetics or sedation during the 
procedure. Through those sheaths, quadripolar catheters were advanced into the heart under 
fluoroscopic guidance using the standard procedures and techniques that have been established 
for clinical electrophysiology studies.  Blood pressure was monitored every 10 minutes with an 
inflatable cuff on the upper arm.  The 3 catheters were placed in the right atrium, in the region of 
the His bundle, and in the right ventricle.  Placement was confirmed fluoroscopically and with 
continuous monitoring of the intracardiac electrograms.  After a 15-minute baseline period, sinus 
node recovery times, atrial effective refractory period (AERP), AV node refractoriness and 
Wenckebach cycle length, His-Purkinje reserve, and ventricular effective refractory period 
(VERP) were measured. Standard protocols for programmed electrical stimulation were used.  
Pacing was performed at twice diastolic threshold.  Atrial ERP measurements were performed 
from the high right atrial location at two drive cycle lengths: 600 ms and 400 ms.  Premature 
impulses were delivered after a drive train of 8 impulses.   The degree of prematurity was 
increased (the coupling interval was shortened) in 10 ms decrements until failure to capture was 
noted on two consecutive runs.  Ventricular programmed stimulation was performed in the exact 
same fashion from the RV apex.
After the initiation of the IV infusion of MK-0448 or placebo, sets of atrial and  
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ventricular effective refractory period measurements were made every 20 minutes.  After each 
set of effective refractory period measurements, PK samples were obtained from the side ports of 
the femoral venous sheaths.  At the end of the 2-hour infusion, measurements of sinus node 
recovery times, AERP, AV node refractoriness and Wenckebach cycle length, His-Purkinje 
reserve, and VERP were repeated.  In the hour following the discontinuation of the infusion, 
additional sets of AERP and VERP measurements were made every 20 minutes along with PK 
sampling.  The catheters were then removed, the venous sheaths were removed, hemostasis was 
attained by manual compression, and the subjects were transported back to the Clinical Research 
Unit (CRU) where they were monitored overnight. 
Confirmatory In Vivo Studies in Dogs: Atrial Refractoriness in Anesthetized Dogs with 
Vagal Nerve Stimulation
A follow-up study in anesthetized dogs was specifically designed to assess the influence of 
autonomic tone on the effects of MK-0448 on atrial refractoriness. In order to control autonomic 
status in the present study, the ?-chloralose/pentobarbital anesthetic regimen used in the previous 
cardiac electrophysiologic study in dogs was replaced with an ?-chloralose/morphine regimen to 
preclude effects of pentobarbital on vagal tone, and nadolol was administered to control 
sympathetic tone.  Mongrel dogs (male or female, 6.7-12.0 kg) were anesthetized with ?-
chloralose (100 mg/kg i.v.) and morphine (2 mg/kg i.m.), and ventilated with room air via an 
endotracheal tube. The left and right femoral veins were cannulated for blood sampling and for 
treatment infusion, and the left femoral artery was cannulated for blood pressure monitoring. Pin 
electrodes were attached for the monitoring of Lead II ECG. Both cervical vagal nerve trunks 
were isolated and ligated rostrally. Bipolar hook electrodes composed of 0.25-mm-diameter 
Teflon-coated silver wire, with insulation removed at the terminal 1-2 mm, were inserted into the 
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middle of each vagal nerve by means of 18 gauge hypodermic needles. The vagal nerve
electrodes were advanced caudally within and parallel to vagal fibers for several centimeters. A 
left thoracotomy was performed at the 4th intercostal space, and the heart was exposed following 
pericardial incision and cradled. A stainless steel epicardial bipolar electrode was sutured to the 
right atrium for pacing, and a stainless steel epicardial quadripolar electrode was sutured to the 
left atrium for sensing left atrial electrograms and for the determination of AET and ARRP (2 
msec pulse duration, 2x AET, 150 bpm pacing rate). Following surgical preparation, a bolus dose 
of 0.5 mg/kg nadolol i.v. was administered, and the preparation was allowed to equilibrate for 20 
min.
At 30 min following surgical preparation, animals were randomized to i.v. treatment 
infusion with either vehicle alone (n=4, 25% aqueous hydroxypropyl-ß-cyclodextrin, 10 ml 
infused over 30 min) or 1.0 ?g/kg/min MK-0448 administered in identical vehicle and infusion 
rate (n=4, in vehicle of 25% aqueous hydroxypropyl-ß-cyclodextrin, 10 ml infused over 30 min). 
Based on previous studies with MK-0448 in chloralose/pentobarbital-anesthetized dogs, the 1.0 
?g/kg/min i.v. infusion was expected to elicit a robust increase in atrial refractory period in the 
absence of alteration in autonomic tone. The following measurements were obtained at baseline 
(pretreatment) and at 15 and 30 min of treatment infusion: heart rate, Lead II ECG intervals 
including QTc using Bazett’s formula, AET and ARRP. At each time point in both groups, 
measurements were obtained sequentially during bilateral vagal stimulation (5.0 volts, 0.1 msec 
pulse duration) at vagal nerve stimulation frequencies of 0 Hz (i.e. no vagal pacing), 2 Hz and 5 
Hz. In the MK-0448 treatment groups, blood samples were drawn at baseline (pretreatment) and 
at 15 and 30 min of infusion for the determination of plasma [MK-0448].  
Changes in ARRP are expressed as percentage changes from baseline within indicated
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vagal nerve stimulation frequency. 
Results
Specificity of MK-0448 for Kv1.5 channels and its associated current, IKur  
MK-0448 targeted Kv1.5, the major pore-forming subunit underlying native IKur, with an IC50 of 
8.6 nM for recombinant human Kv1.5 (hKv1.5) heterologously expressed in CHO cells (Figure 
1).  Similarly, MK-0448 potently inhibited IKur in human atrial myocytes with an IC50 of 10.8 
nM.  MK-0448 also demonstrated a potent effect on currents associated with other Kv1.x and 
Kv2.x subunits, such as Kv1.7 and Kv2.1, with voltage clamp-derived IC50 values of 72 nM and 
61 nM, respectively (Table 1).
While MK-0448 strongly blocked IKur, its effect on other cardiac currents was much 
weaker, indicating a high degree of selectivity for IKur.  Compared with the low-nM range for 
IKur, MK-0448 IC50 ????????????????????M-range for other cardiac currents including IKr
(heterologously expressed hERG; voltage-clamp IC50 = 110 ?M), ITO (heterologously expressed 
Kv4.3; voltage-clamp IC50 = 2.3 ???? INa (heterologously expressed SCN5a; inactive up to 10 
??), Kv3.2 (voltage-clamp IC50 = 6????M), and IKCa (voltage-clamp IC50 = 10???M).  Although 
MK-0448 was generally highly selective against currents expressed in the cardiac ventricles, it 
did exhibit moderate inhibition of the slowly activating cardiac delayed rectifier K+ current, IKs,
with an IC50 of 0.79 ?M (determined by voltage clamp experiments in HEK-293 cells with stable 
co-expression of the ion channel subunits hKCNQ1 and hKCNE1).  Activity against IKs,
however, was seen at a 70-fold higher concentration of MK-0448 than inhibition of IKur. 
Selective Effect of MK-0448 on ARRP in Anesthetized Dogs
Since MK-0448 demonstrated selectivity for IKur versus ventricular ion channel currents, we 
investigated whether atrial repolarization might be prolonged preferentially to ventricular 
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repolarization in 3 anesthetized mongrel dogs (two male and one female, 20-26 kg).  The effects 
of MK-0448 were assessed in comparison to vehicle-matched control infusions.  Continuous i.v. 
infusions of MK-0448 at doses of 0.30 and 0.45 ?g/kg/min resulted in exposure-dependent 
increases in atrial refractory period (ARRP) without changes in ventricular refractory period 
(VRRP); heart rate; mean arterial pressure; or ECG PR, QRS, and QTc intervals.  At a plasma 
concentration of approximately 36 nM, MK-0448 increased ARRP by 10%.   In contrast, a mean 
plasma concentration of ~6 ?M was required to produce changes from baseline of ~5% in VRRP 
and QTc. Increases in mean arterial pressure ~15-20 mmHg compared with controls were also 
noted at the elevated plasma concentration of ~6 ?M.
Figure 2 shows an integrated PK-PD plot of exposure versus change in ARRP and VRRP
from experiments in anesthetized dogs.  The vertical dashed lines indicate the magnitude of the 
window between the exposures that selectively affect the atrium versus exposures that affect 
both atrium and ventricle.  These data indicate that at exposures of MK-0448 that are associated 
with up to an approximate 20% prolongation of ARRP, there is no appreciable effect on 
ventricular repolarization.  These data further suggest that effects on ventricular repolarization 
are seen at exposures of MK-0448 that are approximately 100-fold above those that prolong 
atrial repolarization. 
Effect of MK-0448 on Atrial Fibrillation in a Dog Heart Failure Model
To directly investigate the antiarrhythmic effects of MK-0448 in the dog model, atrial fibrillation 
was induced by atrial burst pacing in dogs with heart failure produced by rapid, sustained right 
ventricular pacing. The cardiac hemodynamic status of these rapid ventricular pacing-induced 
heart failure dogs has been described previously, and was characterized by an increase in left 
ventricular end diastolic pressure, and decreases in left ventricular systolic pressure and +dP/dt.10
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Sustained AF in this model was terminated in two of three animals tested with intravenous doses 
of 0.03 mg/kg i.v. (termination at 30 sec after administration) and 0.1 mg/kg i.v. MK-0448 
(termination at 90 sec after administration), yielding plasma concentrations of 1.7 and 5.9 ?M
respectively at the times of AF termination (Figure 3). In the third animal, AF failed to terminate 
after the administration of sequential intravenous doses up to 1.0 mg/kg MK-448 on two separate 
study dates, yielding plasma concentrations of 16.9-18.7 ?M at 5 minutes after the final dose.
Furthermore, in that series none of the seven vehicle-treated controls converted to sinus 
rhythm.10 These data suggest that concentrations of MK-0448 that yield significant ARRP 
prolongation and no or minimal lengthening of VRRP in the dog may be suitable for acute 
conversion of atrial fibrillation. 
Safety, Tolerability and Pharmacokinetic findings of MK-0448 in Healthy Young Human 
Subjects
Given the selectivity of MK-0448 for atrial repolarization and its anti-arrhythmic effects in the 
dog model, MK-0448 was tested in Phase I studies for its electrophysiologic effects in humans.  
There were 24 healthy, male subjects (age range 23-44 years) who participated in Part 1 of the 
trial.  In part 2, there were 6 subjects enrolled.  Four subjects discontinued the trial; 1 subject 
discontinued due to a benign accelerated idioventricular rhythm, 1 subject withdrew for personal 
reasons, and another subject was lost to follow up.  An additional subject discontinued Part II 
due to an adverse experience of atrial fibrillation that occurred during baseline programmed 
electrical stimulation, prior to dosing.
Supplemental Tables 1 and 2 (Appendix 2) show adverse experiences for Part 1 and 2, 
respectively.  There were no serious adverse experiences and no discontinuations due to adverse 
experiences. All adverse experiences were transient and mild in intensity.  The most common 
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adverse experience was irritation at the site of injection.  Mean AUC0-? and concentration at the 
end of the infusion (Ceoi) appear to increase proportionally with dose through 100 mg to maximal 
????????????????????? and 5726 nM, respectively (Supplemental Table 3; Appendix 2).   
Electrophysiologic Effects of MK-0448 in Healthy Young Human Subjects
An invasive electrophysiologic assessment was incorporated into Part II of the study to directly 
measure the effect of MK-0448 on atrial and ventricular refractory periods.  In Part II, 5 of the 6 
enrolled subjects completed dosing; 1 subject did not dose because of the onset of an AE that 
occurred before dosing that was unrelated to study medication.  The 5 completed subjects were 
administered ascending doses of up to 32 mg of MK-0448 over a 2-hour infusion.  In contrast to 
expectations, there were no increases in AERP or VERP at any dose of MK-0448 (Table 2; 
?????????????????????????????????????????????????????????????????????????????????????????????
at the highest administered dose.  Results for individual patients in the study are in Supplement 
Figure 1.  Thus, despite preclinical data suggesting that MK-0448 preferentially prolongs atrial 
repolarization in a heart failure dog model, there was no evidence that MK-0448 influenced atrial 
(or ventricular) repolarization in healthy human volunteers ?????????????????????????????
(corresponding to > 50-fold higher than the concentration at which significant AERP 
prolongation was observed in the dog). 
Interaction of MK-0448 and Vagal Nerve Stimulation on Atrial Repolarization in 
Anesthetized Dogs
Because the human subjects tested in Phase I were healthy, young, and presumably had high 
vagal tone, and that heart failure is known to be associated with vagal withdrawal, we 
hypothesized that vagal stimulation might influence the effect of IKur blockade on prolongation 
of atrial repolarization.  Accordingly, a follow-up study in anesthetized dogs was specifically 
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designed to assess the influence of autonomic tone, and in particular vagal nerve stimulation, on 
the effects of MK-0448 on atrial refractoriness. As expected, enhanced parasympathetic neural 
tone produced by bilateral vagal nerve stimulation in the dog model resulted in vagal 
stimulation-dependent decreases in heart rate and ARRP. In the absence of vagal nerve 
???????????????????????????????? ?-0448 produced robust (approximately 20 msec, 20%) 
increases in ARRP at both 15 and 30 min of infusion. In contrast, increases in ARRP in the MK-
0448 group during both 2 and 5 Hz vagal nerve stimulation were diminished markedly as 
compared with the absence of vagal stimulation, such that during 2 Hz and 5 Hz vagal nerve 
stimulation, increases in ARRP were comparable in the MK-0448 and vehicle treatment groups. 
Figure 5 compares percent changes in ARRP from baseline in the vehicle and MK-0448 
treatment groups, respectively, at 30 min of treatment infusion. In the vehicle-treatment group, 
only slight increases in ARRP were observed over the duration of the study both in the absence 
and presence of vagal nerve stimulation.  Overall, these data suggest that the effect of IKur
blockade on atrial repolarization is exquisitely sensitive to vagal stimulation and may be 
completely abolished in the setting of enhanced parasympathetic neural tone.  
Discussion
The management of atrial fibrillation involves the choice of rate control or rhythm control.4
Clinical trials have demonstrated that for many antiarrhythmic agents, rhythm control does not 
confer outcomes benefits over rate control,16-20 but these observations are likely due to poor 
efficacy and/or toxicity associated with currently available rhythm control options.17 The 
challenge presented to researchers is to develop treatments that restore and maintain normal 
sinus rhythm without the complications that limit widespread use of the currently available
methods.  In the search for pharmacologic mechanisms that are selective and therefore offer 
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greater safety and tolerability compared with available treatments, IKur blockade is among the 
most investigated.8 Several small molecule agents that block IKur have been in development and 
have been tested in preclinical settings 21, 22.  In this study, we investigated whether specific 
inhibition of IKur might impact on human atrial electrophysiologic properties and hence represent 
a potential therapeutic target for the prevention of AF.
In preclinical studies, MK-0448 demonstrated a selective inhibition of Kv1.5, the major 
pore-forming subunit of the native cardiac atrial repolarizing current, IKur, which is expressed in 
human atrial tissue, but not in ventricular tissue.  This finding is a significant achievement 
considering that the targets of available therapies, which include IKr and IKs, are expressed in 
ventricular as well as atrial tissue, and thus impact on ventricular refractoriness at therapeutic 
exposures.  
Preclinical studies established a relatively high selectivity for IKur vs. other cardiac 
channels; while moderate inhibition of IKs was detected, there appears to be a 30- to 100-fold 
window in preclinical experiments between exposures that have a significant and potentially 
therapeutic effect on atrial refractoriness and exposures that are associated with small but 
measurable changes in ventricular refractoriness.  Preclinical in vivo experiments demonstrated 
selectivity for increasing atrial refractory period at plasma concentrations far below those at 
which changes in ventricular refractory period were observed. Moreover, studies in conscious 
dogs with sustained atrial fibrillation in the setting of heart failure demonstrated that in AF 
terminated in 2 out of 3 dogs after IV administration of MK-0448.   
Based on preclinical results demonstrating a selective increase in atrial refractory period, 
we conducted human studies of MK-0448 to determine safety tolerability, pharmacokinetics and 
effects on atrial and ventricular electrophysiology.  While invasive techniques are not common in 
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first-in-human settings, this approach allowed for determination of whether MK-0448 had any 
target effect in the atria, if there is a ventricular effect, and to help guide dose selection for future 
studies.  Indeed, we found only one other study that performed invasive diagnostic 
electrophysiology evaluation in 23 healthy volunteers.23  That study also included placement of 
an intra-arterial catheter for blood pressure monitoring, and the authors did not report on any 
complications.
MK-0448 was generally well tolerated in our FIH study.  However, no increase in atrial 
or ventricular refractory period was observed despite pharmacologic confirmation of exposure.  
These results were not expected given the atrial effects observed in preclinical studies.  One 
possible explanation for the difference in preclinical and clinical effects on atrial refractoriness is 
that elevated vagal tone in the young healthy patients included in the study may have masked or 
diminished the role of IKur in atrial repolarization, whereas the preclinical data were obtained in a 
heart failure model.  While tests to definitively determine high vagal tone for the volunteers in 
this study were not done, the following observations can be made: the subjects were all 23-44 
years of age and generally healthy, characteristics that are reliably consistent with high vagal 
tone 24; marked respirophasic sinus arrhythmia was noted in all subjects during the EP study, 
which is a well-known marker of preserved vagal tone. 25, 26
To examine the possibility that high vagal tone had an effect on our results, we conducted 
a follow-up study of atrial refractoriness in anesthetized dogs (without heart failure) in the 
absence and presence of bilateral vagal nerve stimulation.  While healthy conscious resting dogs 
have high vagal tone, our invasive electrophysiology study was performed in anesthetized dogs.  
In the absence of vagal nerve stimulation, MK-0448 administration resulted in an increase in 
atrial refractory period, as observed in previous preclinical experiments.  In the presence of vagal 
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nerve stimulation, however, increases in atrial refractory period were greatly attenuated.  These 
results suggest that IKur blockade by MK-0448 is diminished with enhanced parasympathetic 
neural tone.  The mechanism whereby enhanced vagal tone ameliorates the effect of IKur
blockade on refractory period may involve a shortening of the atrial action potential duration as a 
result of increasing IKACh.27  Conversely, it is also possible that MK-0448 is most effective in the 
presence of enhanced sympathetic tone, as seen in heart failure.
Loss of IKur blockade by MK-0448 in states of enhanced vagal tone presents a challenge 
for maintaining therapeutic efficacy, given the purported pro-fibrillatory effects of vagal 
stimulation.  In the dog model, vagal stimulation shortens the atrial ERP in a non-homogeneous 
manner,28 so that under states of high vagal tone, the atria demonstrate inhomogeneity of 
refractoriness. In this milieu, premature impulses will “fractionate” or propagate non-uniformly, 
setting up reentrant rotors that initiate AF.  Withdrawal of vagal tone will often result in 
cessation of AF in the dog model.29
Limitations:
Important limitations of this study are that confounding influences including sympathetic tone, 
age, and species differences may account for differences between results in dog and human 
experiments. Indeed there is substantial variability in parameters tested not only between species, 
but also within species.  It is noteworthy that in the full series of heart failure animals with 
sustained AF tested with two prototype IKur blockers TAEA and ISQ-1, the IKr blocker MK-
499 and the Class IC anti-arrhythmic agent propafenone, no test agent was found to be 
universally effective in terminating AF in all animals tested, suggesting animal-to-animal 
differences in substrate for AF.  Thus the limited numbers of animals tested in this study may 
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have initially given the impression that MK-0448 may have effectively suppressed atrial 
fibrillation.
Additionally, our FIH study included young, healthy volunteers, a population that is 
unlikely to develop AF. Although “lone” AF can occur in younger patients without associated 
heart disease (often associated with high vagal tone), this is almost invariably a benign and self-
terminating arrhythmia.  The majority of AF occurs in older patients with coexisting heart 
disease (hypertension, cardiomyopathy, heart failure, valvular lesions, following thoracic 
surgery, etc.), and is associated with an elevated risk of stroke.  The pathogenesis of these two 
broad categories of AF has diverse mechanisms, and it remains to be proven that a drug that 
targets a single channel in healthy hearts would have comparable electrophysiologic and 
antiarrhythmic effects in diseased hearts.
In summary, extensive preclinical experience with MK-0448 demonstrated that inhibition 
of IKur was generally well tolerated and produced increased atrial refractory period without 
ventricular effects.  This study demonstrated a lack of electrophysiologic effects of specific 
blockade of Kv1.5 in healthy human subjects, as evidenced by a lack of significant effect on 
atrial refractoriness.  This may have been due to diminished contribution of IKur to atrial
repolarization in the presence of enhanced parasympathetic tone; alternately, blockade of Kv1.5 
by MK-0448 may only be manifest in the setting of enhanced sympathetic tone.  This study 
provides evidence of the feasibility, value, and safety of diagnostic EP studies in healthy 
volunteers in early clinical assessments of novel compounds.  These data suggest that, depending 
on the conditions of study including autonomic tone, commonly used preclinical models 
focusing on atrial electrophysiology may lack clinical translatability. Furthermore, targeting IKur
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may be of limited therapeutic value for the prevention of AF due to sensitivity of effect to 
parasympathetic tone.  
Acknowledgments: The authors would like to acknowledge Martha Carroll Vollmer, MA, of 
Merck who provided editorial and administrative support.  
Funding Source: These studies and analyses were supported by Merck Sharp & Dohme Corp., 
Inc., Whitehouse Station, NJ.
Conflict of Interest Disclosures: NL, JJL, JS, MB, CR, GS, LF, PL, AM, JAW, DEG, and DB 
are current or former employees of Merck & Co., Inc., who may own stock and/or hold stock 
options in the Company. 
References:
1. Vidaillet H, Granada  JF, Chyou PH, Maassen K, Ortiz M, Pulido JN, Sharma P, Smith, PN, 
Hayes J. A population-based study of mortality among patients with atrial fibrillation or flutter. 
Am J Med.  2002;113:365-370. 
2. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf, PA D'Agostino RB, Murabito JM, 
Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure 
and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-
2925.
3. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks 
associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med.
2002;113:359-364. 
4. FusterV, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le 
Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr., 
Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA Nishimura R, Ornato JP, Page RL, 
Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein 
K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. ACC/AHA/ESC
2006 guidelines for the management of patients with atrial fibrillation--executive summary: a 
report of the American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines 
(Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial 
Fibrillation). J Am Coll Cardiol. 2006;48:854-906. 
5. Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A. Pharmacological cardioversion of
atrial fibrillation: current management and treatment options. Drugs. 2004;64:2741-2762. 
DOI: 10.1161/CIRCEP.111.969782
22
6. Singh SN, Patrick J, Patrick J. Antiarrhythmic Drugs. Curr Treat Options Cardiovasc Med.
2004;6:357-364. 
7. Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, Cohen JD, 
Capone RJ, Wyse DG. Mortality following ventricular arrhythmia suppression by encainide, 
flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac 
Arrhythmia Suppression Trial (CAST). JAMA. 1993;270:2451-2455. 
8. Burashnikov A, Antzelevitch C. New pharmacological strategies for the treatment of atrial 
fibrillation. Ann Noninvasive Electrocardiol. 2009;14:290-300. 
9. Wang Z, Fermini B, Nattel, S. Sustained depolarization-induced outward current in human 
atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned 
channel currents. Circ Res. 1993;73:1061-1076. 
10. Regan CP, Kiss L, Stump GL, McIntyre CJ, Beshore DC, Liverton NJ, Dinsmore CJ, Lynch 
JJ Jr. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-
[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-
1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure. J Pharmacol 
Exp Ther. 2008;324:322-330. 
11. Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, Sattiraju S, 
Ballew, JD, Jahangir A, Terzic A. Kv1.5 channelopathy due to KCNA5 loss-of-function 
mutation causes human atrial fibrillation. Hum Mol Genet. 2006;15:2185-2191. 
12. Burashnikov A, Antzelevitch C. Can inhibition of IKur promote atrial fibrillation? Heart 
Rhythm. 2008;5:1304-1309. 
13. Wettwer E, Hala O, Christ T, Heubach JF, Dobrev D, Knaut M, Varro A, Ravens U. Role of 
IKur in controlling action potential shape and contractility in the human atrium: influence of 
chronic atrial fibrillation. Circulation. 2004;110:2299-2306. 
14. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug 
Discov. 2006;5:1034-1049. 
15. Regan CP, Stump GL, Wallace AA, Anderson KD, McIntyre CJ, Liverton NJ, Lynch JJ Jr. In 
vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-
1, in rat, dog, and nonhuman primate. J Cardiovasc Pharmacol. 2008;49:236-245. 
16. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U. 
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the 
Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690-
1696.
17. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, 
Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, 
DOI: 10.1161/CIRCEP.111.969782
23
Shemanski L, Waldo AL, Wyse DG. Relationships between sinus rhythm, treatment, and 
survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) 
Study. Circulation. 2004;109:1509-1513. 
18. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--
Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet.
2000;356:1789-1794. 
19. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, 
Achremczyk P. Rate control vs rhythm control in patients with nonvalvular persistent atrial 
fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) 
Study. Chest. 2004;126:476-486. 
20. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, 
Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ. A comparison of rate control and rhythm 
control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-
1840.
21. Ford JW, Milnes JT. New drugs targeting the cardiac ultra-rapid delayed-rectifier current 
(IKur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc 
Pharmacol. 2008, 52:105–120. 
22. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-
arrhythmic drugs, investigational agents, and innovative approaches. Europace. 2008, 10: 647–
665.
23. Insulander P, Vallin H. Gender differences in electrophysiologic effects of mental stress and 
autonomic tone inhibition: a study in health individuals. J Cardiovasc Electrophysiol.
2005;16:59-63. 
24. Korkushko OV, Shatilo VB, Plachinda Yul, Shatilo TV.  Autonomic control of cardiac 
chronotropic function in man as a function of age: assessment by power spectral analysis of heart 
rate variability. J Auton Nerv Sys. 1991;32:191–198 
25. Hayano J, Sakakibara Y, Yamada A, Yamada M, Mukai S, Fujinami T, Yokoyama K, 
Watanabe Y, Takata K. Accuracy of assessment of cardiac vagal tone by heart rate variability in 
normal subjects. Am J Cardiol. 1991;67:199–204 
26. Toska K, Eriksen M. Respiration-synchronous fluctuations in stroke volume, heart rate and 
arterial pressure in humans. J Physiol .1993;472:501-512 
27. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial 
fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325. 
28. Takahashi Y, Jaïs P, Hocini M, Sanders P, Rotter M, Rostock T, Hsu LF, Sacher F, Clémenty 
J, Haïssaguerre M. Shortening of fibrillatory cycle length in the pulmonary vein during vagal  
DOI: 10.1161/CIRCEP.111.969782
24
excitation. J Am Coll Cardiol. 2006; 47: 774-780  
29.  Katsouras G, Sakabe M, Comtois P, Maguy A, Burstein B, Guerra PG, Talajic M, Nattel S. 
Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia 
remodeling. Heart Rhythm. 2009; 6:1465-72 
Table 1. Activity of MK-0448 on Ion Channels 
Channel/Subunits Assay Method IC50
Human Kv1.5                 (n ????? Patch clamp 0.009 ?M
Human IKur                                 (n ??? Patch clamp 0.011 ?M
IKs (KCNQ1+KCNE1)   (n ???? Patch clamp 0.790 ?M
IKr (hERG)                      (n ???? Patch clamp 110 ?M
IKr (hERG)                       (n ??? Binding >30 ?M
Ito (Kv4.3)                       (n ???? HT (High Throughput) Clamp 2.336 ?M
INa (SCN5a)                    (n ???? VIPR (Voltage/Ion Probe Reader) No effect @ 10 ?M
Kv3.2                             (n ???? HT Clamp 6.074 ?M
IKCa                                                 (n ???? Patch clamp 10.2 ?M
Kv2.1                             (n ???? HT Clamp 0.061 ?M
Kv1.7             (n ???? HT Clamp 0.072 ?M
NR1a/2B                        (n ??? FLIPR (Fluorescent Imaging Plate Reader) 6.8 ?M
* n refers to the number of measurements at each concentration tested to define the full concentration response curve and thereby 
determine the IC50; in cases where n ???, at least 3 observations were made at each concentration, but commonly it might be 
more, e.g. as many as 6 or 7 at some concentrations, focused on the range between  20 -80 % inhibition, to define the IC50 more 
precisely
Table 2.  Slopes for individual AERP at pacing cycle lengths of 400 ms and 600 ms and VERP 
400 and 600 vs. plasma concentration of MK-0448 
PD Parameters Estimate ( 95% CI ) Residual error 
variance(msec2)
AERP400 Intercept 186.16 (169.32, 203.01)
49.35Slope 0.0035 (-0.0025, 0.0094)
AERP600 Intercept 202.76 (173.51, 232.02)
117.25Slope 0.0004 (-0.0087, 0.0096)
VERP400 Intercept 209.22 (191.93, 226.51)
48.45Slope 0.0022 (-0.0037, 0.0081)
VERP600 Intercept 227.40 (204.78, 250.01)
72.92Slope 0.0042 (-0.0031, 0.0114)
DOI: 10.1161/CIRCEP.111.969782
25
Figure Legends: 
Figure 1. Effect of MK-0448 on Recombinant hKv1.5 in Conventional Patch Clamp 
Experiments (IC50 Values).  MK-0448 targeted Kv1.5 with an IC50 of 8.6 nM (at 3 Hz and 28.0 
nM at 1 Hz) for recombinant human Kv1.5 (hKv1.5) heterologously expressed in CHO cells.
Figure 2. Integrated PK-PD plot of MK-0448 plasma concentration versus change in ARRP and 
VRRP from experiments in anesthetized dogs.  The vertical dashed lines indicate the magnitude 
of the window between the exposures that selectively affect the atrium versus exposures that 
affect both atrium and ventricle.   
Figure 3. Sample electrocardiographic tracings from dog heart failure model and effect of 
treatment with MK-0448. Panels A, B, and C show readings for placebo before and Panels D, E, 
and F show readings for MK-0448.  Panels A and D show baseline readings before induction of 
AF.  Panels B and E show readings after induction of AF and before dosing.  Panels C and F 
show the effect of medication after dosing.  In Panel F conversion from AF to sinus rhythm is 
observed. 
Figure 4.  Scatter plots for observed individual AERP at pacing cycle lengths of 400 ms (Panel 
A) and 600 ms (Panel B) and VERP 400 (Panel C) and 600 (Panel D) vs. plasma concentration 
of MK-0448 with associated linear regression lines. No significant relationship was exhibited 
between AERP or VERP at either of the analyzed pacing cycle lengths and drug concentration.  
Figure 5. Percentage change in atrial relative refractory period at 30 min (% change from 
baseline at indicated vagal nerve pacing frequency) in dogs with vagal nerve stimulation





